# Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Study · id `cardio:ct-nct06866236` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06866236](<https://clinicaltrials.gov/study/NCT06866236>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06866236

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3000 participants.

## Technical summary

Registry record NCT06866236. Randomized; single masking; primary purpose treatment. Start 2025-10 (anticipated); primary completion 2026-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 3000 participants (planned count; ClinicalTrials.gov record NCT06866236, source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)
- Planned start: 2025-10 (anticipated) (ClinicalTrials.gov record NCT06866236, source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)
- Primary completion: 2026-10 (anticipated) (ClinicalTrials.gov record NCT06866236, source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)
- Completion: 2027-07 (anticipated) (ClinicalTrials.gov record NCT06866236, source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06866236, source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06866236-2025-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
- Acronym: NAD agent
- Condition: Chronic Kidney Diseases
- Condition: Acute Kidney Injury
- Condition: Kidney Failure
- Intervention (Drug): QRX-3
- Lead sponsor: Ebima Clifford Okundaye
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: f53dd2994a4a40b1cb5431b5549a87008f89063421b7b0acf7aa2163135645ad
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
